help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Steingold, K. A.
Right arrow Articles by Judd, H. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Steingold, K. A.
Right arrow Articles by Judd, H. L.

Journal of Clinical Endocrinology & Metabolism, Vol 61, 627-632, Copyright © 1985 by Endocrine Society


ARTICLES

Treatment of hot flashes with transdermal estradiol administration

KA Steingold, L Laufer, RJ Chetkowski, JD DeFazio, DW Matt, DR Meldrum and HL Judd

A randomized prospective double blind study was performed to assess the ability of a transdermal therapeutic system (TTS) delivering estradiol (E2) to suppress hot flashes (HFs) in symptomatic postmenopausal women. Patients were given placebo or E2 in four doses for a 20-day period, and serum gonadotropin and estrogen levels and the occurrences of HFs were measured. Administration of placebo had no measurable effect on either estrogen or gonadotropin levels or the occurrence of HFs. A dose- response relationship was found between the rate of E2 administered and the circulating level of E2, with 25, 50, 100, and 200 micrograms/24 h dosages raising the mean E2 concentrations from mean baseline levels of 5-8 pg/ml to 18, 38, 73, and 100 pg/ml, respectively. Estrone levels also increased with TTS application, but to a lesser extent than did E2 levels. Dose-response reductions of FSH and LH with increasing amounts of E2 administration occurred, but gonadotropin levels were not lowered in any of the patients into the ranges found in premenopausal women. TTS application significantly suppressed the occurrence of HFs at the 50 micrograms/24 h dosage and higher. A significant negative correlation (r = 0.6045; P less than 0.001) between E2 levels and the rates of occurrence of HFs was found during hormone administration. Based on this regression, 50% and 100% reductions of HFs should occur at 61 and 122 pg/ml E2. These data indicate that the transdermal delivery of E2 with these systems significantly reduced the occurrence of HFs and allowed definition of the therapeutic range of hormone replacement in terms of lost ovarian function, as reflected by circulating E2 levels.


This article has been cited by other articles:


Home page
Hum ReprodHome page
N. Yesildaglar, S. Erkaya, D. Uygur, K. Gol, B. Bingol, and Z. Gunenc
Efficacy of pulsed estrogen therapy in relatively younger patients with surgically induced menopause
Hum. Reprod., January 1, 2004; 19(1): 210 - 213.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Vehkavaara, T. Hakala-Ala-Pietila, A. Virkamaki, R. Bergholm, C. Ehnholm, O. Hovatta, M.-R. Taskinen, and H. Yki-Jarvinen
Differential Effects of Oral and Transdermal Estrogen Replacement Therapy on Endothelial Function in Postmenopausal Women
Circulation, November 28, 2000; 102(22): 2687 - 2693.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
J. C. Prior
Perimenopause: The Complex Endocrinology of the Menopausal Transition
Endocr. Rev., August 1, 1998; 19(4): 397 - 428.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1985 by The Endocrine Society